FDA Inspection 998259 — Roswell Park Cancer Institute Corporation. Div. of Pathology

Roswell Park Cancer Institute Corporation. Div. of Pathology — FEI 1372120

The FDA completed an inspection of Roswell Park Cancer Institute Corporation. Div. of Pathology on January 13, 2017 in Buffalo, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
January 13, 2017
Fiscal Year
2017
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Buffalo, NY (United States)